Tag: ticker

FORT WORTH, Texas, July 11, 2025 (GLOBE NEWSWIRE) -- FirstCash Holdings, Inc. (“FirstCash” or the “Company”) (Nasdaq: FCFS), a leading international operator of over 3,000 retail pawn stores in the U.S. and Latin America, today announced that it has reached a settlement with the Consumer Financial Protection Bureau (“CFPB”) regarding alleged violations of the Military Lending Act.

Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA"

Kyiv, New York, Dubai, and Philadelphia – July 10, 2025 – VEON Ltd. (Nasdaq: VEON) (“VEON”), a global digital operator, and Cohen Circle Acquisition Corp. I (“Cohen Circle”), a special purpose acquisition company (Nasdaq: CCIR), today announce the execution of non-redemption agreements (“NRAs”) totaling approximately USD 52.3 million with accredited institutional investors, including Helikon and Clearline. These commitments cover approximately 5.05 million CCIR Class A shares, securing the minimum USD 50 million cash condition for the proposed business combination of Kyivstar Group Ltd (“Kyivstar Group”) and Cohen Circle (the “Business Combination”).

Singapore, July 10, 2025 (GLOBE NEWSWIRE) -- Delixy Holdings Limited (Nasdaq: DLXY) (the “Company” or “Delixy”), a Singapore-based company engaged in the trading of oil related products, today announced the closing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares, par value US$0.000005 per share, (“Ordinary Shares”), 1,350,000 of which were offered by the Company and 650,000 by the selling shareholders Mega Origin Holdings Limited (as to 325,000 Ordinary Shares) and Novel Majestic Limited (as to 325,000 Ordinary Shares) (the “Selling Shareholders”), at a public offering price of US$4.00 per Ordinary Share, raising total gross proceeds of US$8 million in the aggregate to the Company and Selling Shareholders.

SINGAPURA, July 10, 2025 (GLOBE NEWSWIRE) -- Origin Investment Corp I (“Perusahaan”), sebuah perusahaan akuisisi bertujuan khusus yang baru dibentuk, hari ini mengumumkan penutupan penawaran umum perdana (“IPO”) atas 6.000.000 unit dengan harga penawaran sebesar $10,00 per unit, di mana setiap unit terdiri atas satu saham biasa dan setengah waran yang dapat ditebus. Unit-unit tersebut mulai diperdagangkan di Nasdaq Global Market (“Nasdaq”) pada tanggal 2 Juli 2025 dengan simbol ticker “ORIQU”. Setiap satu waran utuh memberikan hak kepada pemegangnya untuk membeli satu saham biasa dengan harga $11,50 per saham, dengan ketentuan dapat disesuaikan sebagaimana dijelaskan dalam prospektus. Hanya satu waran utuh yang dapat digunakan untuk menebus saham. Waran-waran tersebut akan dapat digunakan untuk menebus saham 30 hari setelah penyelesaian kombinasi bisnis awal Perusahaan, dan akan kedaluwarsa lima tahun setelah penyelesaian kombinasi bisnis awal Perusahaan atau lebih cepat jika dilakukan penebusan atau likuidasi oleh Perusahaan. Setelah sekuritas yang terdiri dari unit-unit tersebut mulai diperdagangkan secara terpisah, saham biasa dan waran akan diperdagangkan di Nasdaq dengan simbol “ORIQ” dan “ORIQW”. Tidak ada waran pecahan yang akan diterbitkan pada saat pemisahan unit dan hanya waran utuh yang akan diperdagangkan. Selain itu, Perusahaan telah memberikan opsi 45 hari kepada pihak penjamin emisi untuk membeli hingga 900.000 unit tambahan pada harga IPO untuk menutupi kelebihan penjatahan saham, jika ada.

Investors can contact the law firm at no cost to learn more about recovering their losses

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.